Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012.

PMID:
29523670
2.

Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).

Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW.

Clin Cancer Res. 2018 Mar 15;24(6):1486-1499. doi: 10.1158/1078-0432.CCR-17-2312. Epub 2018 Jan 8.

PMID:
29311117
3.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.

Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

PMID:
29045554
4.

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A.

J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158.

PMID:
28982747
5.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8.

PMID:
28800861
6.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

PMID:
28558150
7.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Apr;15(4):433-451.

PMID:
28404755
8.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

9.

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA.

Biomed Opt Express. 2017 Jan 4;8(2):555-569. doi: 10.1364/BOE.8.000555. eCollection 2017 Feb 1.

10.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG.

Oncologist. 2017 Jan;22(1):25-32. doi: 10.1634/theoncologist.2016-0229. Epub 2016 Oct 27.

11.

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.

Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP.

Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14.

12.

Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.

Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman PA, Yodh AG, Chung SH, Schnall M, Snyder BS, Hylton N, Boas DA, Carp SA, Isakoff SJ, Mankoff D; ACRIN 6691 investigators.

Cancer Res. 2016 Oct 15;76(20):5933-5944. Epub 2016 Aug 15.

13.

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A.

JAMA Oncol. 2016 Nov 1;2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897. Review.

14.

Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Mar;14(3):324-54.

PMID:
26957618
15.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.

Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.

16.

NCCN Guidelines Insights Breast Cancer, Version 1.2016.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.

PMID:
26656517
17.

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2.

18.

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.

Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR, Xiao Y, Shames DS, Mocci S, Chen M, Schmid P.

Ann Oncol. 2015 Sep;26(9):1904-10. doi: 10.1093/annonc/mdv263. Epub 2015 Jul 22.

PMID:
26202594
19.

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.

Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, Jammallo LS, Brunelle CL, O'Toole JA, Isakoff SJ, Specht MC, Taghian AG.

Breast Cancer Res Treat. 2015 Jun;151(2):393-403. doi: 10.1007/s10549-015-3408-1. Epub 2015 May 5.

20.

Breast Cancer Version 2.2015.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2015 Apr;13(4):448-75.

PMID:
25870381
21.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

22.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Calvo E.

Br J Cancer. 2014 Nov 25;111(11):2058-66. doi: 10.1038/bjc.2014.508. Epub 2014 Oct 7.

23.

Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.

Duda DG, Ancukiewicz M, Isakoff SJ, Krop IE, Jain RK.

J Natl Cancer Inst. 2014 Jul 31;106(8). pii: dju187. doi: 10.1093/jnci/dju187. Print 2014 Aug. No abstract available.

PMID:
25082335
24.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.

Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.

PMID:
24827126
25.

Breast cancer version 3.2014.

Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network Breast Cancer Panel.

J Natl Compr Canc Netw. 2014 Apr;12(4):542-90.

PMID:
24717572
26.

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL.

J Clin Oncol. 2014 Apr 20;32(12):1202-9. doi: 10.1200/JCO.2013.54.0518. Epub 2014 Mar 24.

27.

Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system.

Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ.

Biomed Opt Express. 2013 Nov 22;4(12):2911-24. doi: 10.1364/BOE.4.002911. eCollection 2013.

28.

Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review.

Fan L, Liedke PE, Isakoff SJ, St Louis J, Ryan PD, Goss PE.

Clin Breast Cancer. 2014 Apr;14(2):e41-5. doi: 10.1016/j.clbc.2013.10.009. Epub 2013 Oct 25. Review. No abstract available.

PMID:
24342729
29.

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.

Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer EP, Krop IE, Golshan M.

Breast Cancer Res Treat. 2013 Sep;141(2):255-9. doi: 10.1007/s10549-013-2682-z. Epub 2013 Sep 13.

PMID:
24026859
30.

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011).

Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21.

31.

Breast cancer, version 3.2013: featured updates to the NCCN guidelines.

Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Jul;11(7):753-60; quiz 761.

32.

Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients.

Specht MC, Miller CL, Skolny MN, Jammallo LS, O'Toole J, Horick N, Isakoff SJ, Smith BL, Taghian AG.

Ann Surg Oncol. 2013 Sep;20(9):2835-41. doi: 10.1245/s10434-012-2828-y. Epub 2013 May 21.

PMID:
23689935
33.

Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial.

MacDonald SM, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, Smith BL, Yeap BY, Adams J, Delaney TF, Kooy H, Lu HM, Taghian AG.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):484-90. doi: 10.1016/j.ijrobp.2013.01.038. Epub 2013 Mar 21.

PMID:
23523326
34.

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Science. 2013 Feb 1;339(6119):580-4. doi: 10.1126/science.1228522.

35.

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.

Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ.

Breast Cancer Res Treat. 2012 Nov;136(1):169-78. doi: 10.1007/s10549-012-2256-5. Epub 2012 Sep 23.

36.

Case records of the Massachusetts General Hospital. Case 27-2012. A 60-year-old woman with painful muscle spasms and hyperreflexia.

Byrne TN, Isakoff SJ, Rincon SP, Gudewicz TM.

N Engl J Med. 2012 Aug 30;367(9):851-61. doi: 10.1056/NEJMcpc1114036. No abstract available.

PMID:
22931320
37.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):821-9.

38.

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.

Domchek SM, Mitchell G, Lindeman GJ, Tung NM, Balmaña J, Isakoff SJ, Schmutzler R, Audeh MW, Loman N, Scott C, Friedlander M, Kaufman B, Garber JE, Tutt A, Robson ME.

J Clin Oncol. 2011 Nov 10;29(32):4224-6. doi: 10.1200/JCO.2011.36.8134. Epub 2011 Sep 19. No abstract available.

PMID:
21931031
39.

PARP inhibition outside of BRCA mutation carriers.

Isakoff SJ.

Clin Adv Hematol Oncol. 2010 Nov;8(11):757-8. Review. No abstract available.

PMID:
21326153
40.

Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.

Isakoff SJ, Baselga J.

J Clin Oncol. 2011 Feb 1;29(4):351-4. doi: 10.1200/JCO.2010.31.6679. Epub 2010 Dec 20. No abstract available.

PMID:
21172881
41.

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.

Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.

EMBO Mol Med. 2010 May;2(5):146-58. doi: 10.1002/emmm.201000070.

42.

Triple-negative breast cancer: role of specific chemotherapy agents.

Isakoff SJ.

Cancer J. 2010 Jan-Feb;16(1):53-61. doi: 10.1097/PPO.0b013e3181d24ff7. Review.

43.

A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.

Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD.

Invest New Drugs. 2009 Dec;27(6):565-70. doi: 10.1007/s10637-009-9220-1. Epub 2009 Feb 13.

PMID:
19214387
44.

Identification of novel pro-migratory, cancer-associated genes using quantitative, microscopy-based screening.

Naffar-Abu-Amara S, Shay T, Galun M, Cohen N, Isakoff SJ, Kam Z, Geiger B.

PLoS One. 2008 Jan 23;3(1):e1457. doi: 10.1371/journal.pone.0001457.

45.

Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer.

Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, Raphael J, Jepson D, Koundinya M, Rolfs A, Taron B, Isakoff SJ, Brugge JS, LaBaer J.

J Proteome Res. 2006 Mar;5(3):599-610.

46.

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS.

Cancer Res. 2005 Dec 1;65(23):10992-1000.

47.

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC.

Cancer Cell. 2004 Jun;5(6):607-16.

48.

The B cell SH2/PH domain-containing adaptor Bam32/DAPP1 is required for T cell-independent II antigen responses.

Fournier E, Isakoff SJ, Ko K, Cardinale CJ, Inghirami GG, Li Z, Curotto de Lafaille MA, Skolnik EY.

Curr Biol. 2003 Oct 28;13(21):1858-66.

49.

Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains.

Ferguson KM, Kavran JM, Sankaran VG, Fournier E, Isakoff SJ, Skolnik EY, Lemmon MA.

Mol Cell. 2000 Aug;6(2):373-84.

50.

Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains.

Kavran JM, Klein DE, Lee A, Falasca M, Isakoff SJ, Skolnik EY, Lemmon MA.

J Biol Chem. 1998 Nov 13;273(46):30497-508.

Supplemental Content

Loading ...
Support Center